https://acmrjournal.com/index.php/acmr/issue/feed Advances in Clinical Medical Research 2022-04-13T04:43:17+00:00 Dr Megha Garg editor.chief.acmr@gmail.com Open Journal Systems <p><strong>Advances in Clinical Medical Research (ACMR)</strong> is an open-access, freely accessible, online and print quarterly peer-reviewed international journal publishes a wide spectrum of advanced research on all medical specialties including ethical and social issues. ACMR is a gateway to enlighten the latest research/issues happening all around the world of medical and health sciences.</p> https://acmrjournal.com/index.php/acmr/article/view/39 The Use of Leukotriene Inhibitors as Basic Therapy in Children with Bronchial Asthma 2022-04-13T04:43:17+00:00 Zebo Norboboevna Sherova zebo.sherova73@mail.ru Kamola Yuldasheva Normatova kamolaismatova@list.ru Kamala Shakhamdamovna Shaabidova shaabidova1987@gmail.com <p>In the pharmacotherapy of bronchial asthma, a ”step-by-step” approach is recommended, which includes an increase or decrease in the volume of therapy, depending on the severity of clinical symptoms. In complex therapy, it is possible to use non-drug methods of treatment, although the effectiveness of some of them is debatable and needs further study. To achieve this goal, children over the age of 3 years (the group of patients consisted of 26 children) with different forms and degrees of severity of bronchial asthma were included in the study. Patients of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the main group took L-Montus (montelukast), children of the ketotifen comparison group. Leukotriene receptor antagonists (montelukast, zafirlukast) are the first mediator-specific therapy of AD and represent a new therapeutic class of drugs in the treatment of the disease. The effectiveness of leukotriene receptor antagonists has been proven in randomized clinical trials among adults and children with bronchial asthma. Leukotriene receptor blockers, in particular L-Montus relieves the symptoms of AD and is a drug for the basic therapy of this disease, leads to a significant improvement in control, reduces the frequency of exacerbations of AD caused by viral infection in children aged 3-5 years. It has an anti-inflammatory effect, complementary to the action of glucocorticosteroids.</p> 2022-04-13T00:00:00+00:00 Copyright (c) 2022 Author